We found both markers to be useful in the prediction of thymic carcinomas if CD5 and/or CD117 were expressed in at least 50% or 10% of tumor cells, respectively, even though CD5 did not add any additional value to CD117. The gene discussed is KIT; the disease is thymic carcinoma.